MedPage Treatment with the antiviral remdesivir (Veklury) plus dexamethasone was linked to fewer deaths among patients hospitalized for COVID-19 compared with dexamethasone monotherapy, a retrospective study suggested.
Using propensity score matching, the drug duo was associated with an overall 26% reduction in mortality at 14 days (adjusted HR 0.74, 95% CI 0.69-0.78, P<0.0001) and an overall 24% reduction at 28 days (aHR 0.76, 95% CI 0.72-0.81, P<0.0001) when compared with dexamethasone alone, reported Andre Kalil, MD, MPH, of the University of Nebraska Medical Center in Omaha, and colleagues in Clinical Infectious Diseases
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.